LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA7500-LBA7500 ◽  
Author(s):  
James Chih-Hsin Yang ◽  
Martin H. Schuler ◽  
Nobuyuki Yamamoto ◽  
Kenneth John O'Byrne ◽  
Vera Hirsh ◽  
...  
Keyword(s):  
Phase Iii ◽  
First Line ◽  
Open Label ◽  
Daily News ◽  
Activating Mutations ◽  
Adenocarcinoma Of The Lung ◽  
Open Label Phase ◽  
Phase Iii Study ◽  
Final Text ◽  
First Line Treatment

LBA7500 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA671-LBA671 ◽  
Author(s):  
Karen A. Gelmon ◽  
Frances Boyle ◽  
Bella Kaufman ◽  
David Huntsman ◽  
Alexey Manikhas ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Open Label ◽  
Daily News ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Open Label Phase ◽  
Final Text

LBA671 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA9007-LBA9007 ◽  
Author(s):  
Tony Mok ◽  
Ying Cheng ◽  
Xiangdong Zhou ◽  
Ki Hyeong Lee ◽  
Kazuhiko Nakagawa ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Daily News ◽  
Phase Iii Trial ◽  
Open Label Phase ◽  
Final Text

The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA8003-LBA8003
Author(s):  
Ralph Zinner ◽  
Helen J. Ross ◽  
Robert Weaver ◽  
Ramaswamy Govindan ◽  
Viran R. Holden ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Open Label ◽  
Daily News ◽  
Online Supplement ◽  
Open Label Phase ◽  
Phase Iii Study ◽  
Final Text

LBA8003 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document